Oslo, Norway, June 16, 2022 - Nykode Therapeutics ASA (Oslo Stock Exchange
(OSE): NYKD), a clinical-stage biopharmaceutical company dedicated to the
discovery and development of vaccines and novel immunotherapies, today announced
that it has been uplisted to the main list of the Oslo Stock Exchange (OSE) with
first day of trading today, June 16, 2022. Nykode Therapeutics had traded on the
Euronext Growth trading platform in Oslo since October 2020.
"Today, Nykode reached a significant inflection point, signaling our growth as a
leading member of the biotech industry in Europe. Nykode's uplisting to the main
list of the Oslo Stock Exchange enables us to reach a broader base of global
institutional investors, increase liquidity of the Company's shares, and better
showcase our value proposition as a leading immunotherapy company with a unique
and highly differentiated technology platform," commented Michael Engsig, Chief
Executive Officer.
Watch our video to learn more: https://nykode.com/about-us/company-profile.
About Nykode Therapeutics
Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to
the discovery and development of vaccines and novel immunotherapies for the
treatment of cancer and infectious diseases. Nykode's modular vaccine technology
specifically targets antigens to Antigen Presenting Cells, which are essential
for inducing rapid, strong and long-lasting antigen specific immune responses
and eliciting efficacious clinical responses.
Nykode's lead product candidates are VB10.16, a therapeutic vaccine for the
treatment of human papilloma virus (HPV)-16 induced malignancies which
demonstrated positive interim efficacy and safety results from its Phase II
trial for the treatment of cervical cancer